Progenicyte Therapeutics
IL - ChicagoBiotechnology
Focus: Progenicyte Therapeutics is a newly founded (2024) stem cell and cell/gene therapy biotech based in Chicago. The company appears to have acquired or is managing marketed radiopharmaceutical assets (AZEDRA, PYLARIFY) alongside pipeline development.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Progenicyte Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Progenicyte Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Progenicyte Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Radiopharmaceutical approved NDA in peak revenue phase; provides immediate commercial traction for a 2024-founded company.
Help build intelligence for Progenicyte Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.